Dr. Wang Discusses FLT3 Mutations in AML

Eunice Wang, MD
Published: Sunday, Jun 25, 2017



Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses FLT3 mutations in acute myeloid leukemia (AML).

In a study of patients with FLT3-mutated AML, crenolanib was combined with standard chemotherapy. There was an initial high response rate, and the drug was fairly well tolerated.

There is a lot of heterogeneity in the FLT3 mutations that AML patients can present with, says Wang. Additionally, there are data suggesting that these mutations can predict resistance to other TKIs.
 


Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses FLT3 mutations in acute myeloid leukemia (AML).

In a study of patients with FLT3-mutated AML, crenolanib was combined with standard chemotherapy. There was an initial high response rate, and the drug was fairly well tolerated.

There is a lot of heterogeneity in the FLT3 mutations that AML patients can present with, says Wang. Additionally, there are data suggesting that these mutations can predict resistance to other TKIs.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x